July 12, 2006
http://www.michaeljfox.org/news/arti...p?id=234&sec=4

The LRRK2-G2019S Mutation: Opening a Novel Era in Parkinson's Disease Genetics

By Vincenzo Bonifati, Department of Clinical Genetics, Erasmus MC Rotterdam, The Netherlands. From European Journal of Human Genetics (advance online publication)

The role of genetic factors in the etiology of Parkinson's disease has long been considered negligible, but a series of recent discoveries are dramatically changing this view. Two studies recently published in The New England Journal of Medicine report an astonishing high prevalence of a single mutation in leucine-rich repeat kinase 2 (LRRK2), G2019S, in North African Arabs and Ashkenazi Jews with PD (1,2).

Mutations in the LRRK2 gene were first identified in 2004 in families with autosomal-dominant PD (3,4); soon thereafter, the G2019S mutation (c.G6055A) was identified by several groups as a common cause of this disease, being found not only in 5–6% of familial PD but also in 1–2% of sporadic PD in several European and US populations (5,6,7,8,9).

In one of the novel studies (2), 22 out of 120 Ashkenazi Jewish patients with PD (18.3%, 95% confidence intervals (CI) 11.9–26.4) and four of 317 controls (1.3%, CI 0.34–3.2) carried the G2019S mutation. The risk of developing PD increased 17.6-fold (CI 5.9–52.2) in those who carry the mutation. G2019S was significantly more frequent among familial (29.7%) than sporadic PD probands (13.3%) and a lifetime penetrance of 31.8% was estimated for the mutation. The other study found G2019S in 30 out of 76 Arab PD probands (39%) and two of 151 controls (3%) all from North Africa;1 moreover, 37 and 41% were found to carry the mutation among familial and sporadic PD, respectively. In this case, the odds ratio for developing PD among all G2019S carriers reached an even greater figure of 48.6 (CI 11.2–211.0). The low penetrance and censor effects likely explain the high G2019S prevalence in sporadic PD and its rare occurrence in controls (especially the younger individuals).

The relevance of these values is better appreciated if one considers that PD is the most frequent degenerative movement disorder, with a prevalence approaching 2% in Western countries, in people aged more than 65 years. Being an age-related disease, the number of patients will undoubtedly increase in the future, and PD will become an even bigger public health problem. Although therapies are effective in symptomatic control, none is currently able to stop or slow down the disease progression.

In most patients PD is sporadic, but in 10–15% of cases it runs in families, and more rarely, it segregates as a Mendelian trait with either autosomal-dominant or -recessive inheritance. Mutations in the -synuclein gene cause autosomal-dominant forms, whereas mutations in the parkin, DJ-1 and PINK1 gene cause autosomal-recessive forms. Parkin mutations are frequent in cases of early onset, but mutations in all the above-mentioned genes are very rare in the patients with the classic, late-onset PD form (10).

LRRK2 is the first gene that is frequently mutated in autosomal-dominant PD of late onset (11). In addition, the discovery of G2019S established for the first time the proof-of-principle for a genetic determinant frequently involved in sporadic PD (7,8,12). The evidence that G2019S is pathogenic is overwhelming. This mutation is very frequent in PD and extremely rare in controls (5,6,7,8,12), and it cosegregates with PD in large families (6,8,13). The G2019 residue is extremely conserved in LRRK2 homologs and the mutation increases the kinase activity of the protein (14).

However, the prevalence of G2019S is population specific: very rare in Asia (15), low in Northern Europe (8) and high in Italy (12), Spain (16) and Portugal (17). Haplotype analyses revealed that all carriers of this mutation inherited the same ancestral chromosome (8, 12, 18).

After these two latest studies, it is clear that the prevalence of G2019S is highest among Arabs patients from North Africa and among Ashkenazi Jewish, also suggesting likely regions of origin of the mutation.

If the reported data will be confirmed, this mutation represents the most important known determinant of PD in several populations. However, the CI for the prevalence estimates are still wide. It is important to study a larger series of cases and ethnically matched controls, to refine and extend these figures. It is also crucial to assess the penetrance of the mutation more accurately. Earlier figures obtained in selected samples of dominant families were likely overestimated,8 and values should be calculated in unselected, consecutive series, ideally from population-based studies. Screening in other populations can reveal further clues about the origin of this founder mutation. The astonishing figures obtained in Arabs and Ashkenazi Jews raise the question whether a positive selection is also shaping the population prevalence of G2019S in North Africa and the Middle East.

The discovery of G2019S has set the stage for PD entering fully the field of medical genetics. However, whether and when G2019S testing might be used for genetic counselling should await a much deeper understanding of the mechanisms of the disease caused by this and other LRRK2 mutations, and of the factors governing their penetrance.

Likely, other secrets concerning how G2019S causes PD remain to uncover. A few carriers of the G2019S mutation also carry parkin gene mutations (1, 13). Digenic or polygenic inheritance could explain the lack of a Mendelian pattern of inheritance in most PD families. We do not currently understand the mechanisms underlying the large variability in onset age and other clinical features, observed even among the members of the same G2019S family; other factors must modify the expression and progression of the disease. In this sense, the G2019S mutation recapitulates the complexity of PD etiology in general. But now that so many PD cases can be identified with a common genetic determinant, it will be easier to design screens for modifiers.

Unravelling the pathobiology of the LRRK2-related PD might have far-reaching consequences for all patients with PD. Initial findings suggest that PD-causing mutations increase the kinase activity of the LRRK2 protein (14,19). Protein kinases are good targets for small-molecule drugs, and modulating the LRRK2 activity could become an innovative therapeutic strategy for all patients with PD.

But perhaps the most important implication of the G2019S mutation, which is now strengthened by the studies in Arabs and Ashkenazi Jews, is a conceptual one: to have brought the etiology of familial and sporadic PD closer than they have ever been

Public release date: 11-Sep-2006

Two copies of G2019S Parkinson's gene mutation doesn't lead to more severe disease

http://www.eurekalert.org/pub_releas...-tco090806.php

No observable differences between homozygous and heterzygous state

A group of Parkinson's disease researchers concluded there are no observable differences between those who have two copies of the most common mutation of the recently discovered LRRK2 gene and those who have only one copy. Their study will be published in the September edition of the Archives of Neurology.

In most diseases with a genetic cause or component, two copies of a bad gene lead to more severe visible manifestation of the disease. Researchers expected to see worse symptoms, the disease start earlier in life and a shorter life span for those with two copies of the LRRK2 gene with the G2019S mutation. "That proved not to be the case," says Mayo Clinic neurologist Zbigniew Wszolek, M.D.

Wszolek formed an international consortium that compared the clinical features of Parkinson's disease in the two groups. "It's puzzling," he says. "More studies are needed. More patients need to be identified and, hopefully, more basic science research is going to be performed to find out why."

The G2019S mutation is the most common of the 20 identified LRRK2 disease–causing mutations. There are six known genes that cause familial Parkinson's disease, but only one, the G2019S mutation of the LRRK2 gene, has been associated with previously unexplained cases of Parkinson's disease. Wszolek and his colleagues hope that studying the ways in which these genes cause disease, especially the G2019S mutation, will lead to improved treatments and even a cure. "We are all united by the common drive to learn more about this disease, to help the people with this illness and to bring us closer to curative treatments," Wszolek says. "And this may be a step in that direction."

By pooling their studies from around the globe, Wszolek and his colleagues found 26 people with the G2019S mutation in both copies of their LRRK2 gene--one inherited from the mother and the other from the father. Interestingly, three patients with the dual mutation exhibited no clinical signs of Parkinson's disease, an indication that the gene has incomplete penetrance.

This concept means having the gene mutation alone does not lead to developing severe symptoms or even developing any signs of the disease 100 percent of the time. "One may need some additional factors, either genetic or environmental, which work either to produce the disease or to protect one from developing it," Wszolek says.

This latest finding supports the theory many hold that the majority of Parkinson's disease cases may only be explained by the interaction of a number of genes or a genetic and environmental interaction.

Wszolek and his colleagues found all patients in their study, whether they had one or two G2019S mutations, had asymmetric onset of symptoms, most often tremor, no male or female preponderance, and both groups had a similar range in the age in which symptoms began.

In 2004 Wszolek was one of the researchers who discovered the LRRK2 gene caused parkinsonism. He was also part of the team that discovered the G2019S mutation causes parkinsonism in several North American and European families. That was the first time a genetic cause had been associated with typical, late-onset Parkinson's disease.